article Open AccessTop 1% cited
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Clinical Cancer Research · 2015 · Vol. 22(4) · pp. 886–894
Morganna Freeman-Keller✉(University of South Florida)Young‐Chul Kim(Moffitt Cancer Center)Heather Cronin(Moffitt Cancer Center)Allison Richards(Moffitt Cancer Center)Geoffrey T. Gibney(Vince Lombardi Cancer Clinic)Jeffrey S. Weber(Moffitt Cancer Center)
Abstract
Cutaneous irAEs are associated with improved survival in melanoma patients treated with nivolumab, and clinical benefit should be validated in larger prospective analyses.
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchMedicineRashInternal medicineNivolumabVitiligoAdverse effectGastroenterologyHazard ratioPneumonitisProportional hazards model
MeSH terms
NivolumabAntibodies, MonoclonalAntineoplastic AgentsExanthemaHumansHypothyroidismMelanomaPneumoniaSkin NeoplasmsMultivariate AnalysisProportional Hazards ModelsTreatment OutcomeMucositisKaplan-Meier Estimate
Funding
- National Cancer Institute
Citations
865
FWCI
25.72
field-weighted impact
References
50
Percentile
100%
vs. same field & year
Citations per year
Cited by
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
Annals of Oncology · 2017 · 898 citations
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Frontiers in Oncology · 2018 · 1,321 citations
Top 10 Challenges in Cancer Immunotherapy
Immunity · 2020 · 2,223 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 3,616 citations
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Nature reviews. Cancer · 2019 · 2,306 citations
References
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
The immune contexture in human tumours: impact on clinical outcome
Nature reviews. Cancer · 2012 · 4,857 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology · 2014 · 2,198 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · 2,648 citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 8,055 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.